Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Jefferies said it still regards GSK’s fundamental value as “compelling,” adding that its 2027+ estimates for sales and ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The U.K. firm, whose vaccines include Arexvy and Shingrix, now expects 2024 vaccine sales to decrease by a low-single digit percentage. GSK's (GSK) shares are falling 4% in premarket trading ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...